{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T14:00:09Z","timestamp":1762956009697},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,11,8]],"date-time":"2018-11-08T00:00:00Z","timestamp":1541635200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Diab Rep"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s11892-018-1114-1","type":"journal-article","created":{"date-parts":[[2018,11,8]],"date-time":"2018-11-08T04:44:05Z","timestamp":1541652245000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The Evolving Role of the Cardiologist in the Management of Type 2 Diabetes"],"prefix":"10.1007","volume":"18","author":[{"given":"Robert J.","family":"Chilton","sequence":"first","affiliation":[]},{"given":"Kelly M.","family":"Gallegos","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9","family":"Silva-Cardoso","sequence":"additional","affiliation":[]},{"given":"Rene","family":"Oliveros","sequence":"additional","affiliation":[]},{"given":"Son","family":"Pham","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2018,11,8]]},"reference":[{"key":"1114_CR1","unstructured":"Centers for Disease Control and Prevention. New CDC report: more than 100 million Americans have diabetes or prediabetes. Available from: \n                      https:\/\/www.cdc.gov\/media\/releases\/2017\/p0718-diabetes-report.html\n                      \n                    . Accessed 18 July."},{"key":"1114_CR2","unstructured":"National Diabetes Statistic Report, 2017. Estimates of diabetes and its burden in the United States. Available from \n                      https:\/\/www.cdc.gov\/diabetes\/pdfs\/data\/statistics\/national-diabetes-statistics-report.pdf\n                      \n                    . Accessed 30 August."},{"key":"1114_CR3","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.ahj.2004.07.037","volume":"149","author":"PD Savage","year":"2005","unstructured":"Savage PD, Banzer JA, Balady GJ, Ades PA. Prevalence of metabolic syndrome in cardiac rehabilitation\/secondary preventions programs. Am Heart J. 2005;149:627\u201331. \n                      https:\/\/doi.org\/10.1016\/j.ahj.2004.07.037\n                      \n                    .","journal-title":"Am Heart J"},{"key":"1114_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12933-015-0296-y","volume":"14","author":"V Gyberg","year":"2015","unstructured":"Gyberg V, De Bacquer D, De Backer G, Jennings C, Kotseva K, Mellbin L, et al. Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology. Cardiovasc Diabetol. 2015;14:133. \n                      https:\/\/doi.org\/10.1186\/s12933-015-0296-y\n                      \n                    .","journal-title":"Cardiovasc Diabetol"},{"key":"1114_CR5","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","volume":"364","author":"S Yusuf","year":"2004","unstructured":"Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937\u201352. \n                      https:\/\/doi.org\/10.1016\/S0140-6736(04)17018-9\n                      \n                    .","journal-title":"Lancet"},{"key":"1114_CR6","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1007\/s00125-018-4642-y","volume":"61","author":"J Oellgaard","year":"2018","unstructured":"\u2022 Oellgaard J, Gaede P, Rossing P, Rorth R, Kober L, Parving HH, et al. Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21\u00a0years of follow-up in the randomised Steno-2 study. Diabetologia. 2018;61:1724\u201333. \n                      https:\/\/doi.org\/10.1007\/s00125-018-4642-y\n                      \n                    . This study is important because it continues to find significant benefits in global risk reduction.","journal-title":"Diabetologia"},{"key":"1114_CR7","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1007\/s00125-016-4065-6","volume":"59","author":"P Gaede","year":"2016","unstructured":"Gaede P, Oellgaard J, Carstensen B, Rossing P, Lund-Anderson H, Parving HH, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21\u00a0years follow-up on the Steno-2 randomised trial. Diabetologia. 2016;59:2298\u2013307. \n                      https:\/\/doi.org\/10.1007\/s00125-016-4065-6\n                      \n                    .","journal-title":"Diabetologia"},{"key":"1114_CR8","doi-asserted-by":"publisher","unstructured":"Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012;357:2375\u201384. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1211585\n                      \n                    .","DOI":"10.1056\/NEJMoa1211585"},{"key":"1114_CR9","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.jacc.2014.06.1182","volume":"64","author":"GD Dangas","year":"2014","unstructured":"Dangas GD, Farkouh ME, Sleeper LA, Yang M, Schoos MM, Macaya C, et al. Long-term outcome of PCI versus CABG in insulin and non-insulin-treated diabetic patients: results from the FREEDOM trial. J Am Coll Cardiol. 2014;64:1189\u201397. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2014.06.1182\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"key":"1114_CR10","first-page":"837","volume":"12","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;12:837\u201353.","journal-title":"Lancet"},{"key":"1114_CR11","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","volume":"358","author":"A Patel","year":"2008","unstructured":"ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560\u201372. \n                      https:\/\/doi.org\/10.1056\/NEJMoa0802987\n                      \n                    .","journal-title":"N Engl J Med"},{"key":"1114_CR12","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/S0140-6736(10)60576-4","volume":"376","author":"F Ismail-Beigi","year":"2010","unstructured":"Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376:419\u201330. \n                      https:\/\/doi.org\/10.1016\/S0140-6736(10)60576-4\n                      \n                    .","journal-title":"Lancet"},{"key":"1114_CR13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa0808431","volume":"360","author":"W Duckworth","year":"2009","unstructured":"Duckworth W, Abraira C, Moritz T, Red D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129\u201339. \n                      https:\/\/doi.org\/10.1056\/NEJMoa0808431\n                      \n                    .","journal-title":"N Engl J Med"},{"key":"1114_CR14","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S2213-8587(17)30104-3","volume":"5","author":"S Zoungas","year":"2017","unstructured":"\u2022 Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5:431\u20137. \n                      https:\/\/doi.org\/10.1016\/S2213-8587(17)30104-3\n                      \n                    . This study addresses the importance of glucose control for microvascular events.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1114_CR15","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","volume":"358","author":"A Patel","year":"2008","unstructured":"ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J. 2008;358:2560\u201372. \n                      https:\/\/doi.org\/10.1056\/NEJMoa0802987\n                      \n                    .","journal-title":"N Engl J"},{"key":"1114_CR16","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/dom.13030","volume":"20","author":"J Conceicao","year":"2018","unstructured":"\u2022 Conceicao J, Dores J, Araujo F, Laires PA, Carr RD, Brodovicz K, et al. Severe hypoglycaemia among patients with type 2 diabetes requiring emergency hospital admission: the Hypoglycaemia In Portugal Observational Study-Emergency Room (HIPOS-ER). Diabetes Obes Metab. 2018;20:50\u20139. \n                      https:\/\/doi.org\/10.1111\/dom.13030\n                      \n                    . This study shows that hypoglycemia is one of the most important side effects in diabetes treatment with significant morbidity and mortality.","journal-title":"Diabetes Obes Metab"},{"key":"1114_CR17","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"\u2022 Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1504720\n                      \n                    . This trial changed the treatment of type 2 diabetes, placing it alongside other cardiovascular agents.","journal-title":"N Engl J Med"},{"key":"1114_CR18","unstructured":"FDA briefing document: Endocrine and Metabolic Drug Advisory Committee Meeting. June 28, 2016. \n                      https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/UCM508422.pdf\n                      \n                    . Accessed September 10, 2018."},{"key":"1114_CR19","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"JA Dormandy","year":"2005","unstructured":"Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279\u201389. \n                      https:\/\/doi.org\/10.1016\/S0140-6736(05)67528-9\n                      \n                    .","journal-title":"Lancet"},{"key":"1114_CR20","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644\u201357. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1611925\n                      \n                    .","journal-title":"N Engl J Med"},{"key":"1114_CR21","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.2337\/dc17-1551","volume":"41","author":"SE Inzucchi","year":"2018","unstructured":"Inzucchi SE, Iliev H, Pfarr E, Zinman B. Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial. Diabetes Care. 2018;41:e4\u20135. \n                      https:\/\/doi.org\/10.2337\/dc17-1551\n                      \n                    .","journal-title":"Diabetes Care"},{"key":"1114_CR22","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","volume":"368","author":"DJ Drucker","year":"2006","unstructured":"Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696\u2013705. \n                      https:\/\/doi.org\/10.1016\/S0140-6736(06)69705-5\n                      \n                    .","journal-title":"Lancet"},{"key":"1114_CR23","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s13300-018-0370-z","volume":"9","author":"SP Marso","year":"2018","unstructured":"Marso SP, Hardy E, Han J, Wang H, Chilton RJ. Changes in heart rate associated with exenatide once weekly: pooled analysis of clinical data in patients with type 2 diabetes. Diabetes Ther. 2018;9:551\u201364. \n                      https:\/\/doi.org\/10.1007\/s13300-018-0370-z\n                      \n                    .","journal-title":"Diabetes Ther"},{"key":"1114_CR24","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","volume":"130","author":"BM Scirica","year":"2014","unstructured":"Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130:1579\u201388. \n                      https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.010389\n                      \n                    .","journal-title":"Circulation"},{"key":"1114_CR25","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Kober LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247\u201357. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1509225\n                      \n                    .","journal-title":"N Engl J Med"},{"key":"1114_CR26","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228\u201339. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1612917\n                      \n                    .","journal-title":"N Engl J Med"},{"key":"1114_CR27","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311\u201322. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1603827\n                      \n                    .","journal-title":"N Engl J Med"},{"key":"1114_CR28","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834\u201344. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1607141\n                      \n                    .","journal-title":"N Engl J Med"},{"key":"1114_CR29","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S2213-8587(17)30412-6","volume":"6","author":"MA Bethel","year":"2018","unstructured":"Bethel MA, Patel RA, Merrill P, Lokhnygina Y, Buse JB, Mentz RJ, et al. Cardiovascular outcomes with glucagon-like peptine-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2018;6:105\u201313. \n                      https:\/\/doi.org\/10.1016\/S2213-8587(17)30412-6\n                      \n                    .","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Current Diabetes Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11892-018-1114-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-018-1114-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-018-1114-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T00:25:43Z","timestamp":1573172743000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11892-018-1114-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,8]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1114"],"URL":"https:\/\/doi.org\/10.1007\/s11892-018-1114-1","relation":{},"ISSN":["1534-4827","1539-0829"],"issn-type":[{"value":"1534-4827","type":"print"},{"value":"1539-0829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,8]]},"assertion":[{"value":"8 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"144"}}